Abstract:Studies on gene expression in response to therapy have led to the discovery of pharmacogenomics biomarkers and advances in precision medicine. Whole transcriptome sequencing (RNA-seq) is an emerging tool for profiling gene expression and has received wide adoption in the biomedical research community. However, its value in regulatory decision making requires rigorous assessment and consensus between various stakeholders, including the research community, regulatory agencies, and industry. The FDA-led SEquencing Quality Control (SEQC) consortium has made considerable progress in this direction, and is the subject of this review. Specifically, three RNA-seq platforms (Illumina HiSeq, Life Technologies SOLiD, and Roche 454) were extensively evaluated at multiple sites to assess cross-site and cross-platform reproducibility. The results demonstrated that relative gene expression measurements were consistently comparable across labs and platforms, but not so for the measurement of absolute expression levels. As part of the quality evaluation several studies were included to evaluate the utility of RNA-seq in clinical settings and safety assessment. The neuroblastoma study profiled tumor samples from 498 pediatric neuroblastoma patients by both microarray and RNA-seq. RNA-seq offers more utilities than microarray in determining the transcriptomic characteristics of cancer. However, RNA-seq and microarray-based models were comparable in clinical endpoint prediction, even when including additional features unique to RNA-seq beyond gene expression. The toxicogenomics study compared microarray and RNA-seq profiles of the liver samples from rats exposed to 27 different chemicals representing multiple toxicity modes of action. Cross-platform concordance was dependent on chemical treatment and transcript abundance. Though both RNA-seq and microarray are suitable for developing gene expression based predictive models with comparable prediction performance, RNA-seq offers advantages over microarray in profiling genes with low expression. The rat BodyMap study provided a comprehensive rat transcriptomic body map by performing RNA-Seq on 320 samples from 11 organs in either sex of juvenile, adolescent, adult and aged Fischer 344 rats. Lastly, the transferability study demonstrated that signature genes of predictive models are reciprocally transferable between microarray and RNA-seq data for model development using a comprehensive approach with two large clinical data sets. This result suggests continued usefulness of legacy microarray data in the coming RNA-seq era. In conclusion, the SEQC project enhances our understanding of RNA-seq and provides valuable guidelines for RNA-seq based clinical application and safety evaluation to advance precision medicine.

Quality assessment and control of tissue specific RNA-seq libraries of Drosophila transgenic RNAi models

Single Cell RNA-seq Analysis Reveals Temporally-Regulated and Quiescence-Regulated Gene Expression in Drosophila Larval Neuroblasts

Integrating massive RNA-seq data to elucidate transcriptome dynamics in Drosophila melanogaster

Design and Methods of Large-Scale RNA Interference Screens in Drosophila.

Optimized Method for Robust Transcriptome Profiling of Minute Tissues Using Laser Capture Microdissection and Low-Input RNA-Seq

RNA-seq Profiling of Small Numbers of Drosophila Neurons

Systematic assessment of long-read RNA-seq methods for transcript identification and quantification

A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila

Precision and Accuracy of Single-Cell/Nuclei RNA Sequencing Data

Systematic Assessment of Next Generation Sequencing for Quantitative Small RNA Profiling: a Multiple Protocol Study Across Multiple Laboratories

Methods and tools for spatial mapping of single-cell RNAseq clusters in Drosophila

Comprehensive Assessments of RNA-seq by the SEQC Consortium: FDA-Led Efforts Advance Precision Medicine

RNA Interference (RNAi) Screening in Drosophila

An analysis of RNA quality metrics in human brain tissue

Comprehensive Multi-Center Assessment of Small RNA-seq Methods for Quantitative Mirna Profiling

A Drosophila resource of transgenic RNAi lines for neurogenetics.

An Efficient and Multiple Target Transgenic RNAi Technique with Low Toxicity in Drosophila

Single-cell analysis of the nervous system at small and large scales with instant partitions

Microfluidic Single-Cell Whole-Transcriptome Sequencing

Optimized single-nucleus transcriptional profiling by combinatorial indexing

Optimization of library preparation based on SMART for ultralow RNA-seq in mice brain tissues